• Behavioral Health
  • Clinical Insights
  • Treatment

Webinar: What Providers Need to Know: New Medication Options in Behavioral Health

Jul 6th, 2021

Behavioral Drug Approvals in 2020

The FDA’s Center for Drug Evaluation and Research approved 53 new drugs in 2020 alone, including several novel treatments for schizophrenia and other behavioral health conditions. What do providers need to know about these new medications?

Genoa Healthcare’s Chief Procurement Officer Stephanie Kornechuk, PharmD, recently hosted a webinar in which she addressed new behavioral drugs and their unique attributes. To learn more, watch the webinar, which:

  • Reviews 2020 behavioral drug approvals
  • Looks ahead at coming drug trends
  • Covers recent policy changes impacting treatment of opioid use disorder
  • Touches on recent COVID-19 vaccine developments

To learn more about how Genoa can help you and those you serve, contact us today.

Recent Posts

Read More
  • Partnering with Genoa
  • People-first Pharmacy Care
3 reasons to transition your pharmacy to Genoa Healthcare

Having a pharmacy right within your clinic offers a lot of benefits: it can break down barriers to care, improve consumer and provider satisfaction and drive better outcomes for the...
  • Behavioral Health
  • Clinical Insights
  • Treatment
4 things to know about Spravato® (Intranasal esketamine)

On January 21, 2025, the FDA announced the approval of Spravato® nasal spray as a monotherapy treatment for treatment-resistant depression (TRD), making this medication the first and only monotherapy option...
  • Art Celebration
  • Consumer Stories
  • People-first Pharmacy Care
Genoa’s 2024 Art Celebration: Celebrating the healing power of creativity

“I’ve always expressed myself through my art and learned to use my creativity to inspire others”, says Genoa Healthcare 2024 Art Celebration participant Shanelle G. Genoa’s annual Art Celebration invites...

Partner with Genoa
  • Behavioral Health
  • Clinical Insights
  • Treatment
Esketamine: Latest research offers new hope for adolescents with treatment-resistant depression

Adolescents with treatment-resistant depression (TRD) often struggle with a lack of effective treatment options. While ketamine has been shown to help improve outcomes for adults living with major depressive disorder...